

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

August 8, 2019

Janelle D'Alvise Chief Executive Officer Acasti Pharma Inc. 545 Promenade du Centropolis, Suite 100 Laval, Québec, Canada H7T 0A3

> Re: Acasti Pharma Inc. Registration Statement on Form F-3 Filed August 7, 2019 File No. 333-233063

Dear Ms. D'Alvise:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Christine Westbrook at 202-551-5019 with any questions.

Sincerely,

Division of Corporation Finance Office of Healthcare & Insurance

cc: Jason Comerford, Esq.